2 Top Marijuana Stocks That Can Help You Make Money

Key point: focus on company fundamentals and public status—many cannabis businesses remain private, which can reduce liquidity and amplify price moves. High levels of speculation and potential regulatory or unexpected changes mean close monitoring, rigorous due diligence, and cautious position sizing are warranted.

Analysis

Capital flows into the cannabis complex are being rerouted from speculative SPAC/IPO bets toward cash-generative retail and ancillary businesses; this rotation amplifies second-order winners such as retail-focused MSOs with durable cash margins and B2B suppliers that sell to both cannabis and broader horticulture markets. Expect price discovery to happen within 6–18 months as state-level policy changes and bank access drive cash collection and working-capital funding — companies that can fund A&P growth without dilutive equity will outlast highly levered cultivators.

Supply-chain bottlenecks are shifting from cultivation input shortages to distribution and branding battles: real upside accrues to firms that control customer relationships (brick-and-mortar plus loyalty data) and proprietary branded SKUs that can compress shelf turnover by 20–40% vs commodity flower. Conversely, pure-play cultivation names without differentiated brands face margin compression from easier capital raising by larger MSOs and potential downward price pressure if more state markets tip into oversupply.

Key risks are binary policy outcomes and capital-market access: federal banking reform or an unexpected DOJ policy pivot can re-rate the whole sector within days, while structural improvements (eg, 280E tax relief or wholesale marketplace normalizing) play out over years. A pragmatic portfolio should size for both rapid event risk (state ballot results, DOJ/SEC guidance) and a multi-year path to normalization — that implies concentrated, hedged positions rather than broad beta exposure.

Key Decisions for Investors

• Pair trade (6–12 months): Long Trulieve (TCNNF) 6–12 month call spread (buy 1 x at-the-money, sell 1 x 30% OTM) size 2–3% NAV / Short Cronos Group (CRON) 1–2% NAV via puts or short stock. Rationale: favor cash-flow positive MSO + retail moat vs higher multiple, lower-margin international/biotech exposure. Target 30–60% return on the long spread with a 20% stop; hedge ratio 1:1 by notional.
• Ancillary exposure (12–24 months): Buy Scotts Miracle-Gro (SMG) or GrowGeneration (GRWG) weight 2–4% NAV. These trade-off regulated cannabis policy tail risk for diversified revenue streams to legal horticulture; target 25–40% upside if cultivation capex rebounds, stop-loss 15%.
• Event-driven short (30–90 days): Buy out-of-the-money puts on small-cap SPAC-era operators or weed ETF exposure after run-ups around IPO windows (size 1–2% NAV). Rationale: anticipate forced sellers and dilution post-IPO; aim for asymmetric 3:1 payoff if a deal collapses or fresh equity sharply re-prices comps.
• Volatility hedge (30–120 days): Purchase strangle around major state ballot/legislative dates (buy calls and puts on broad cannabis ETF or largest MSO). Cost as insurance ~1–2% NAV per event; protects against 30%+ binary moves in either direction and preserves upside optionality.